NRG-GI011
Open to Accrual
Protocol Information
A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)
Principal Investigator
Nina Sanford
Status
Open to Accrual
Date Opened To Accrual
June 11, 2025
Disease Site
Gastrointestinal [GI] Other
Phase
III
Developmental Therapeutics
No
Primary Objective
To evaluate whether dose-escalated RT improves 3-year overall survival compared to standard treatments without dose-escalated RT, in locally advanced pancreatic cancer patients without radiographic progression and with biochemical response after an initial interval of chemotherapy.
Patient Population
Pathologically (histologically or cytologically) proven
diagnosis of pancreatic ductal adenocarcinoma and locally advanced unresectable
disease as defined per the National Comprehensive Cancer Network guidelines and
institutional tumor board review.
Target Accrual
356
Protocol Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.
Patient Study Webpage
To learn more about this study, visit the Patient Study Webpage.
-
Share this study.
-
-
-
-
